^
Association details:
| Biomarker: | YES1 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 1884: The activation of YES1 leads to the acquired resistance to neratinib in HER2-amplified breast and lung cancers
Published date:
05/15/2020
Excerpt:
YES1, which is a member of the SRC family, was amplified in two neratinib-resistant breast cancer cell lines and one lung cancer cell line.
DOI:
10.1158/1538-7445.AM2020-1884
